IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v24y2006i6p571-591.html
   My bibliography  Save this article

Cost Effectiveness of Enoxaparin as Prophylaxis against Venous Thromboembolic Complications in Acutely Ill Medical Inpatients

Author

Listed:
  • Peter Schädlich
  • Michael Kentsch
  • Manfred Weber
  • Wolfgang Kämmerer
  • Josef Brecht
  • Vijay Nadipelli
  • Eduard Huppertz

Abstract

Objective: To estimate, from the hospital perspective in Germany, the cost effectiveness of the low-molecular-weight heparin (LMWH) subcutaneous enoxaparin sodium 40mg once daily (ENOX) relative to no pharmacological prophylaxis (NPP) and relative to subcutaneous unfractionated heparin (UFH) 5000IU three times daily (low-dose UFH [LDUFH]). Each is used in addition to elastic bandages/compression stockings and physiotherapy in the prevention of venous thromboembolic events (VTE) in immobilised acutely ill medical inpatients without impaired renal function or extremes of body weight. Methods: The incremental cost-effectiveness ratios (ICERs) of the ‘additional cost for ENOX per clinical VTE avoided versus NPP’ and ‘additional cost for ENOX per episode of major bleeding avoided versus LDUFH’ were chosen as target variables. The target variables were quantified using a modelling approach based on the decision-tree technique. Resource use during thromboprophylaxis, diagnosis and treatment of VTEs, episode of major bleeding and secondary pneumonia after pulmonary embolism (PE) was collected from a hospital survey. Costs were exclusively those to hospitals incurred by staff expenses, drugs, devices, disposables, laboratory tests and equipment for diagnostic procedures. These costs were determined by multiplying utilised resource items by the price or tariff of each item as of the first quarter of 2003. Safety and efficacy values of the comparators were taken from the MEDENOX (prophylaxis in MEDical patients with ENOXaparin) and the THE-PRINCE (THromboEmbolism-PRevention IN Cardiac or respiratory disease with Enoxaparin) trials and from a meta-analysis. The evaluation encompassed 8 (6–14) days of thromboprophylaxis plus time to treat VTE and episode of major bleeding in hospital. Point estimates of all model parameters were applied exclusively in the base-case analysis. Results: There were incremental costs of €1106 for ENOX per clinical VTE avoided versus NPP (€1 ≈ $US1.07; average of the first quarter of 2003). ENOX dominated LDUFH: cost savings of €55 825 were obtained and 7.7 episodes of major bleeding were avoided by ENOX compared with LDUFH, each per 1000 patients. In comprehensive sensitivity analyses, the robustness of the model and its results was shown. Conclusions: Results of this evaluation suggest that, in immobilised acutely ill medical inpatients, ENOX may offer hospitals in Germany a very cost-effective option for thromboprophylaxis compared with NPP and a cost-saving alternative compared with LDUFH. Copyright Adis Data Information BV 2006

Suggested Citation

  • Peter Schädlich & Michael Kentsch & Manfred Weber & Wolfgang Kämmerer & Josef Brecht & Vijay Nadipelli & Eduard Huppertz, 2006. "Cost Effectiveness of Enoxaparin as Prophylaxis against Venous Thromboembolic Complications in Acutely Ill Medical Inpatients," PharmacoEconomics, Springer, vol. 24(6), pages 571-591, June.
    • Handle: RePEc:spr:pharme:v:24:y:2006:i:6:p:571-591
    DOI: 10.2165/00019053-200624060-00005
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.2165/00019053-200624060-00005
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.2165/00019053-200624060-00005?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Peter Schädlich & Eduard Huppertz & Josef Brecht, 1998. "Cost-Effectiveness Analysis of Ramipril in Heart Failure after Myocardial Infarction," PharmacoEconomics, Springer, vol. 14(6), pages 653-669, December.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Peter Schädlich & Josef Brecht & Massimo Brunetti & Eva Pagano & Badrudin Rangoonwala & Eduard Huppertz, 2001. "Cost Effectiveness of Ramipril in Patients with Non-Diabetic Nephropathy and Hypertension," PharmacoEconomics, Springer, vol. 19(5), pages 497-512, May.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:24:y:2006:i:6:p:571-591. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.